Niveditha Ravindra
Overview
Explore the profile of Niveditha Ravindra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gui G, Ravindra N, Hegde P, Andrew G, Mukherjee D, Wong Z, et al.
Bone Marrow Transplant
. 2024 Nov;
60(2):154-160.
PMID: 39506075
Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD...
2.
Gui G, Ravindra N, Hegde P, Andrew G, Mukherjee D, Wong Z, et al.
Bone Marrow Transplant
. 2024 Oct;
60(2):144-153.
PMID: 39455897
Routine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for...
3.
Hegde P, Andrew G, Gui G, Ravindra N, Mukherjee D, Wong Z, et al.
Bone Marrow Transplant
. 2024 Oct;
60(2):175-177.
PMID: 39424958
No abstract available.
4.
Dillon L, Gui G, Ravindra N, Andrew G, Mukherjee D, Wong Z, et al.
JAMA Oncol
. 2024 May;
10(8):1104-1110.
PMID: 38696205
Importance: Persistence of FLT3 internal tandem duplication (ITD) in adults with acute myeloid leukemia (AML) in first complete remission (CR) prior to allogeneic hematopoietic cell transplant (HCT) is associated with...
5.
Ravindra N, Dillon L, Gui G, Smith M, Gondek L, Jones R, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):428-430.
PMID: 38182672
No abstract available.
6.
Ravindra N, Dillon L, Gui G, Smith M, Gondek L, Jones R, et al.
medRxiv
. 2023 Sep;
PMID: 37662423
The presence of measurable residual disease (MRD) prior to an allogeneic hematopoietic transplant (alloHCT) in Acute Myeloid Leukemia (AML) has been shown to be associated with an increased risk of...
7.
Gui G, Dillon L, Ravindra N, Hegde P, Andrew G, Mukherjee D, et al.
medRxiv
. 2023 Aug;
PMID: 37577695
Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. The persistence of mutated or -ITD...
8.
Dillon L, Gui G, Page K, Ravindra N, Wong Z, Andrew G, et al.
JAMA
. 2023 Mar;
329(9):745-755.
PMID: 36881031
Importance: Preventing relapse for adults with acute myeloid leukemia (AML) in first remission is the most common indication for allogeneic hematopoietic cell transplant. The presence of AML measurable residual disease...
9.
Maddali M, Kulkarni U, Ravindra N, Arunachalam A, Venkatraman A, Lionel S, et al.
Hematol Oncol Stem Cell Ther
. 2021 Mar;
15(2):13-20.
PMID: 33789164
Objective/background: Recurrent somatic mutations in the JAK2, calreticulin (CALR), and the MPL genes are described as drivers of BCR-ABL1-negative myeloproliferative neoplasms (MPN) that includes polycythemia vera (PV), essential thrombocytosis (ET),...
10.
Benjamin E, Ravindra N, Rajamani B, Anandan S, Kausalya B, Veldore V, et al.
Leuk Lymphoma
. 2021 Jan;
62(6):1528-1531.
PMID: 33478278
No abstract available.